These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

519 related items for PubMed ID: 21071998

  • 1. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
    Yan W, Zhang T, Cheng J, Zhou X, Qu X, Hu H.
    Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
    [Abstract] [Full Text] [Related]

  • 2. The effect of T0901317 on ATP-binding cassette transporter A1 and Niemann-Pick type C1 in apoE-/- mice.
    Dai XY, Ou X, Hao XR, Cao DL, Tang YL, Hu YW, Li XX, Tang CK.
    J Cardiovasc Pharmacol; 2008 May; 51(5):467-75. PubMed ID: 18437096
    [Abstract] [Full Text] [Related]

  • 3. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
    Kappus MS, Murphy AJ, Abramowicz S, Ntonga V, Welch CL, Tall AR, Westerterp M.
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
    [Abstract] [Full Text] [Related]

  • 4. Liver X receptor agonist T0901317 reduces atherosclerotic lesions in apoE-/- mice by up-regulating NPC1 expression.
    Ou X, Dai X, Long Z, Tang Y, Cao D, Hao X, Hu Y, Li X, Tang C.
    Sci China C Life Sci; 2008 May; 51(5):418-29. PubMed ID: 18785587
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
    Chen Y, Duan Y, Yang X, Sun L, Liu M, Wang Q, Ma X, Zhang W, Li X, Hu W, Miao RQ, Xiang R, Hajjar DP, Han J.
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299
    [Abstract] [Full Text] [Related]

  • 6. Elimination of macrophages drives LXR-induced regression both in initial and advanced stages of atherosclerotic lesion development.
    van der Stoep M, Li Z, Calpe-Berdiel L, van der Sluis RJ, Saleh P, McKinnon HJ, Smit MJ, Korporaal SJ, Van Berkel TJ, Van Eck M, Hoekstra M.
    Biochem Pharmacol; 2013 Dec 01; 86(11):1594-602. PubMed ID: 24095721
    [Abstract] [Full Text] [Related]

  • 7. Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144.
    Ramírez CM, Rotllan N, Vlassov AV, Dávalos A, Li M, Goedeke L, Aranda JF, Cirera-Salinas D, Araldi E, Salerno A, Wanschel A, Zavadil J, Castrillo A, Kim J, Suárez Y, Fernández-Hernando C.
    Circ Res; 2013 Jun 07; 112(12):1592-601. PubMed ID: 23519695
    [Abstract] [Full Text] [Related]

  • 8. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
    Honzumi S, Shima A, Hiroshima A, Koieyama T, Terasaka N.
    Biochim Biophys Acta; 2011 Dec 07; 1811(12):1136-45. PubMed ID: 21875689
    [Abstract] [Full Text] [Related]

  • 9. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes.
    Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ, Tontonoz P.
    Proc Natl Acad Sci U S A; 2001 Jan 16; 98(2):507-12. PubMed ID: 11149950
    [Abstract] [Full Text] [Related]

  • 10. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms.
    Verschuren L, de Vries-van der Weij J, Zadelaar S, Kleemann R, Kooistra T.
    J Lipid Res; 2009 Feb 16; 50(2):301-11. PubMed ID: 18757914
    [Abstract] [Full Text] [Related]

  • 11. Knock-down of the oxysterol receptor LXRα impairs cholesterol efflux in human primary macrophages: lack of compensation by LXRβ activation.
    Ishibashi M, Filomenko R, Rébé C, Chevriaux A, Varin A, Derangère V, Bessède G, Gambert P, Lagrost L, Masson D.
    Biochem Pharmacol; 2013 Jul 01; 86(1):122-9. PubMed ID: 23313547
    [Abstract] [Full Text] [Related]

  • 12. Group X secretory phospholipase A2 negatively regulates ABCA1 and ABCG1 expression and cholesterol efflux in macrophages.
    Shridas P, Bailey WM, Gizard F, Oslund RC, Gelb MH, Bruemmer D, Webb NR.
    Arterioscler Thromb Vasc Biol; 2010 Oct 01; 30(10):2014-21. PubMed ID: 20844270
    [Abstract] [Full Text] [Related]

  • 13. LXR Agonist T0901317's Hepatic Impact Overrules Its Atheroprotective Action in Macrophages, Driving Early Atherogenesis in Chow-Diet-Fed Male Apolipoprotein E Knockout Mice.
    Hoekstra M, de Jong LM, van der Geest R, de Leeuw LR, Krisnamurthi R, Geerling JJ, Van Eck M.
    Biomolecules; 2024 Apr 02; 14(4):. PubMed ID: 38672446
    [Abstract] [Full Text] [Related]

  • 14. Unsaturated fatty acids repress expression of ATP binding cassette transporter A1 and G1 in RAW 264.7 macrophages.
    Ku CS, Park Y, Coleman SL, Lee J.
    J Nutr Biochem; 2012 Oct 02; 23(10):1271-6. PubMed ID: 22209005
    [Abstract] [Full Text] [Related]

  • 15. Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting.
    Quinet EM, Savio DA, Halpern AR, Chen L, Schuster GU, Gustafsson JA, Basso MD, Nambi P.
    Mol Pharmacol; 2006 Oct 02; 70(4):1340-9. PubMed ID: 16825483
    [Abstract] [Full Text] [Related]

  • 16. Liver X receptor activation attenuates plaque formation and improves vasomotor function of the aortic artery in atherosclerotic ApoE(-/-) mice.
    Chen J, Zhao L, Sun D, Narsinh K, Li C, Zhang Z, Qi S, Wei G, Li W, Guo W, Cao F.
    Inflamm Res; 2012 Dec 02; 61(12):1299-307. PubMed ID: 22833121
    [Abstract] [Full Text] [Related]

  • 17. Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice.
    Peng D, Hiipakka RA, Dai Q, Guo J, Reardon CA, Getz GS, Liao S.
    J Pharmacol Exp Ther; 2008 Nov 02; 327(2):332-42. PubMed ID: 18723776
    [Abstract] [Full Text] [Related]

  • 18. Ligand, receptor, and cell type-dependent regulation of ABCA1 and ABCG1 mRNA in prostate cancer epithelial cells.
    Trasino SE, Kim YS, Wang TT.
    Mol Cancer Ther; 2009 Jul 02; 8(7):1934-45. PubMed ID: 19531574
    [Abstract] [Full Text] [Related]

  • 19. A novel small molecule liver X receptor transcriptional regulator, nagilactone B, suppresses atherosclerosis in apoE-deficient mice.
    Gui Y, Yao S, Yan H, Hu L, Yu C, Gao F, Xi C, Li H, Ye Y, Wang Y.
    Cardiovasc Res; 2016 Oct 02; 112(1):502-14. PubMed ID: 27460841
    [Abstract] [Full Text] [Related]

  • 20. Identification of a novel partial agonist of liver X receptor α (LXRα) via screening.
    Li N, Wang X, Zhang J, Liu C, Li Y, Feng T, Xu Y, Si S.
    Biochem Pharmacol; 2014 Dec 01; 92(3):438-47. PubMed ID: 25450668
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.